Bue Ross Agner

Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial

Hirotaka Watada, Shizuka Kaneko, Mitsuhisa Komatsu et al. · Diabetes Obesity and Metabolism · 2019 · 30 citations · Full text

Medicine, Endocrinology, Pharmacology +12

Vitamin D deficiency is unrelated to type of atrial fibrillation and its complications.

Faiza Qayyum, Nadia Lander Landex, Bue Ross Agner et al. · PubMed · 2012 · 26 citations

Medicine, Cardiology, Nutritional Sciences +14

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Kohei Kaku, Eiichi Araki, Yukio Tanizawa et al. · Diabetes Obesity and Metabolism · 2019 · 24 citations · Full text

Medicine, Endocrinology, Pharmacology +17

<scp>DUAL II</scp> China: Superior <scp>HbA1c</scp> reductions and weight loss with insulin degludec/liraglutide ( <scp>IDegLira</scp> ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

Pei Yu, Bue Ross Agner, Bin Luo et al. · Diabetes Obesity and Metabolism · 2021 · 21 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17